Praxis Precision Medicines I (PRAX)

$37.69

+1.14

(+3.12%)

Market is closed - opens 7 PM, 20 Jun 2024

Insights on Praxis Precision Medicines I

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 241.2% return, outperforming this stock by 329.9%

Performance

  • $37.15
    $39.91
    $37.69
    downward going graph

    1.43%

    Downside

    Day's Volatility :6.92%

    Upside

    5.56%

    downward going graph
  • $12.75
    $67.21
    $37.69
    downward going graph

    66.17%

    Downside

    52 Weeks Volatility :81.03%

    Upside

    43.92%

    downward going graph

Returns

PeriodPraxis Precision Medicines ISector (Health Care)Index (Russel 2000)
3 Months
-33.02%
0.6%
0.0%
6 Months
124.65%
8.9%
0.0%
1 Year
121.52%
10.2%
0.0%
3 Years
-88.68%
17.8%
-20.9%

Highlights

Market Capitalization
666.7M
Book Value
$17.32
Earnings Per Share (EPS)
-10.95
Wall Street Target Price
137.17
Profit Margin
0.0%
Operating Margin TTM
-9718.33%
Return On Assets TTM
-46.65%
Return On Equity TTM
-85.25%
Revenue TTM
2.2M
Revenue Per Share TTM
0.24
Quarterly Revenue Growth YOY
-36.9%
Gross Profit TTM
0.0
EBITDA
-129.7M
Diluted Eps TTM
-10.95
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-10.1
EPS Estimate Next Year
-9.78
EPS Estimate Current Quarter
-2.08
EPS Estimate Next Quarter
-2.2

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Praxis Precision Medicines I(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 263.94%

Current $37.69
Target $137.17

Technicals Summary

Sell

Neutral

Buy

Praxis Precision Medicines I is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Praxis Precision Medicines I
Praxis Precision Medicines I
-18.8%
124.65%
121.52%
-88.68%
-91.24%
Moderna, Inc.
Moderna, Inc.
-2.21%
61.44%
11.0%
-30.77%
776.11%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.88%
22.86%
33.81%
94.34%
240.92%
Novo Nordisk A/s
Novo Nordisk A/s
5.61%
41.82%
73.65%
241.2%
437.92%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
6.24%
17.06%
38.23%
152.16%
166.21%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Praxis Precision Medicines I
Praxis Precision Medicines I
NA
NA
NA
-10.1
-0.85
-0.47
NA
17.32
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.72
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.58
30.58
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.48
49.48
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.16
31.16
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Praxis Precision Medicines I
Praxis Precision Medicines I
Buy
$666.7M
-91.24%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$53.7B
776.11%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$114.2B
240.92%
30.58
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$636.1B
437.92%
49.48
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$124.1B
166.21%
31.16
39.46%

Institutional Holdings

  • Adage Capital Partners Gp LLC

    8.14%
  • Cormorant Asset Management, LLC

    7.66%
  • Point72 Asset Management, L.P.

    5.58%
  • RA Capital Management, LLC

    4.84%
  • Perceptive Advisors LLC

    4.80%
  • Vanguard Group Inc

    4.35%

Company Information

praxis precision medicines, inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. its lead product candidates include prax-114, an extrasynaptic-preferring gabaa receptor positive allosteric modulator that is in phase iia clinical trial for the treatment of major depressive disorder and perimenopausal depression; and prax-944, a selective small molecule inhibitor of t-type calcium channels, which is in phase iia clinical trial for the treatment of essential tremor. the company is also developing prax-562, a persistent sodium current blocker that is in phase i clinical trial to treat severe pediatric epilepsy and adult cephalgia; prax-222, an antisense oligonucleotide for patients with gain-of-function (gof) scn2a epilepsy; and kcnt1 program for the treatment of kcnt1 gof epilepsy. it has a cooperation and license agreement with rogcon inc.; a license agreement purdue neuroscience company; and a res

Organization
Praxis Precision Medicines I
Employees
82
CEO
Mr. Marcio Silva De'Souza M.B.A.
Industry
Health Technology

FAQs